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In the present work, we used a novel albumin-associated lipoplex formulation, containing the cationic lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-
ethylphosphocholine (EPOPC) and cholesterol (Chol), to evaluate the antitumoral efficacy of two gene therapy strategies: immuno-gene therapy,
mediated by IL-12 gene expression, and “suicide” gene therapy, mediated by HSV-tk gene expression followed by ganciclovir (GCV) treatment.
Our data show that, in an animal model bearing a subcutaneous TSA (mouse mammary adenocarcinoma) tumor, intratumoral administration of the
albumin-associated complexes containing the plasmid encoding IL-12 results in a strong antitumoral effect, as demonstrated by the smaller tumor
size, the higher T-lymphocyte tumor infiltration and the more extensive tumor necrotic and hemorrhagic areas, as compared to that observed in
animals treated with control complexes. On the other hand, the application of the “suicide” gene therapy strategy results in a significant
antitumoral activity, which is similar to that achieved with the immuno-gene therapy strategy, although involving different antineoplastic
mechanisms. For the tested model, albumin-associated complexes were shown to efficiently mediate intratumoral delivery of therapeutic genes,
thus leading to a significant antitumoral effect. This finding is particularly relevant since TSA tumors are characterized for being poorly
immunogenic, aggressive and exhibiting high proliferation capacity.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cancer gene therapy; “Suicide” gene therapy; Immunotherapy; Gene delivery; Cationic liposomes; Transfection1. Introduction
Over the last years, gene therapy has emerged as a promising
strategy for cancer treatment [1,2]. However, some limitations are
associated to the clinical application of gene therapy, the reduced
ability to deliver functional therapeutic genes into target cells
being the major one. Therefore, research in gene therapy has been
focused on the development of suitable carriers that, while
exhibiting adequate features for in vivo use, would also mediate
efficient intracellular delivery of genetic material [3–6].
Cationic liposome/DNA complexes (“lipoplexes”) have
been extensively studied aiming at developing appropriate
non-viral gene delivery systems [7,8]. Much effort has been
devoted to the synthesis of new cationic lipids, selection of⁎ Corresponding author. Tel.: +351 239 820 190; fax: +351 239 853 607.
E-mail address: mdelima@ci.uc.pt (M.C. Pedroso de Lima).
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doi:10.1016/j.bbamem.2006.12.017different helper lipids and association of proteins or fusogenic
peptides aiming at enhancing lipoplex biological activity [4,5].
Our previous observations indicated that association of albumin
to lipoplexes strongly increases their transfection activity,
namely in the presence of serum [9]. Therefore, in this study
we tested the efficacy of an albumin-associated lipoplex
formulation, containing the new cationic lipid EPOPC and
Chol, prepared at the 4/1 lipid/DNA (+/−) charge ratio, in
antitumoral gene therapy strategies.
Among cancer gene therapy approaches, immuno-gene
therapy mediated by IL-12 gene expression and “suicide” gene
therapy mediated by HSV-tk gene expression, followed by
ganciclovir (GCV) treatment, have emerged as promising
strategies for cancer treatment [10–13]. IL-12 plays a key
antitumoral effect by enhancing the proliferation and the
cytotoxic activity of both T and NK cells and inducing the pro-
duction of IFN-γ and other cytokines, resulting, consequently, in
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metastasis formation [10,14,15]. The application of the HSV-tk
“suicide” gene therapy results in the conversion of the prodrug
GCV into a toxic active metabolite that causes cell death. The
cells expressing the HSV-tk metabolize the prodrug to
ganciclovir monophosphate, which is further converted into
ganciclovir triphosphate by cellular kinases. The resulting
guanosin analog either inhibits the DNA polymerase directly
and/or is incorporated into cellular DNA, resulting in chain
termination and tumoral cell death [16–18]. A key feature of this
strategy is the “bystander effect”, by which a high percentage of
tumoral cell death can occur even when only a low percentage of
cells have been transfected [17,19–21].
In the present work, we evaluated the antitumoral activity
resulting from the application of the above mentioned
therapeutic strategies, using a novel albumin-associated lipo-
plex formulation. These studies were performed both in vitro,
by measuring cell viability, and in an animal model, by
determining the tumor size and animal survival, and assessing
both tumoral histology and infiltration of T-lymphocytes.2. Material and methods
2.1. Tumor cell line and mice
TSA is an aggressive and poorly immunogenic cell line established from the
first in vivo transplant of a moderately differentiated mammary adenocarcinoma
that was generated spontaneously in a BALB/c female mouse (a gift of Dr. M.
Colombo, Instituto per lo Studio e la Cura dei Tumor, Milan, Itali) [22]. TSA cells
weremaintained at 37 °C, under 5%CO2, inDulbecco'smodified Eagle'smedium-
high glucose (DMEM-HG) (Irvine Scientific, Santa Ana, CA) supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS) (Sigma, St. Louis,
MO), penicillin (100 U/ml), streptomycin (100 μg/ml) and L-glutamine (4 mM).
TSA cells grow in monolayer and were detached by treatment with a trypsin
solution (0.25%) (SigmaChemical). For in vitro transfection studies, 0.4×105 TSA
cells were seeded in 1 ml of medium in 48-well culture plates, 24 h before
transfection, and used at 50–70% confluence. For in vivo studies, after being
detached by trypsin treated cells were resuspended in saline buffer (PBS), to obtain
a cell density of 500×103 cells/ml. 200 μl of the cell suspension were immediately
injected subcutaneously in the left flank of 8-week-old female BALB/cmice
(Charles River Laboratories, Barcelona, Spain), which were handled in accordance
with the European Community guidelines.
2.2. Preparation of cationic liposomes and their complexes with DNA
Small unilamellar cationic liposomes (SUV) were prepared from a 1:1 (mol
ratio) mixture of EPOPC and Chol, by extrusion of multilamellar liposomes
(MLV). Briefly, lipids (Avanti Polar Lipids, Alabaster, AL) dissolved in CHCl3
were mixed at the desired molar ratio and dried under vacuum in a rotatory
evaporator. The dried lipid films were hydrated with deionized water to a final
lipid concentration of 6 mM (in vitro studies) or 60 mM (in vivo studies) and the
resulting MLV were then sonicated for 3 min and extruded 21 times through two
stacked polycarbonate filters of 50 nm pore diameter using a Liposofast device
(Avestin, Toronto, Canada). The resulting liposomes (SUV) were then diluted
five times with deionized water (in vitro studies) and filter-sterilized utilizing
0.22 μm pore-diameter filters (Schleicher & Schuell). For in vitro studies,
lipoplexes were prepared by sequentially mixing 100 μl of a HEPES-buffered
saline solution (HBS) (100 mM NaCl, 20 mM HEPES, pH 7.4), with liposomes
(volume was dependent on the desired (+/−) lipid/DNA charge ratio) and with
100 μl of HBS solution containing 1 μg of pCMVluc encoding luciferase (a gift
of Dr. P. Felgner (Vical, San Diego, CA)). The mixture was further incubated for
15 min at room temperature. For complexes containing albumin (HSA),
liposomes were pre-incubated with this protein (32 μg HSA/μg of DNA) for15 min, followed by a further 15 min incubation with plasmid DNA solution at
room temperature. Different plasmids were used: pCMVlacZ encoding β-
galactosidase (Gibco BRL, Gaithersburg, USA); pCMVluc (a gift of Dr. P.
Felgner, Vical, San Diego, CA); pCMVIL-12 encoding IL-12 (a gift of Prof. D.
Mahvi, University of Wisconsin-Madison, Madison, USA); pCMVtk encoding
HSV-tk (a gift of Prof. N. Düzgünes, University of Pacific, San Francisco,
USA).
2.3. In vitro transfection activity
TSA cells were covered with 0.3 ml of DMEM-HG before lipid/DNA
complexes were added. The complexes (containing 1 μg of DNA) were added
gently to cells in a volume of 0.2 ml per well. After 4 h incubation (in 5% CO2 at
37 °C) the medium was replaced with DMEM-HG and the cells were further
incubated for 48 h. The cells were then washed twice with phosphate-buffered
saline solution (PBS) and 100 μl of lysis buffer (1 mM DTT; 1 mM EDTA;
25 mM Tris-phosphate (pH=7.8); 8 mM MgCl2; 15% glycerol; 1% (v/v) Triton
X-100) were added to each well. The level of gene expression in the lysates was
evaluated by measuring light production by luciferase in a Mediators PhL
luminometer (Mediators Diagnostika, Vienna, Austria). The protein content of
the lysates was measured by the Dc Protein Assay reagent (Bio-Rad, Hercules,
CA) using bovine serum albumin as the standard. The data were expressed as
RLU of luciferase per mg of total cell protein.
2.4. In vitro antitumoral activity
The in vitro antitumoral activity resulting from transfection of the cells
mediated by HSA-EPOPC:Chol/DNA (+/−) (4/1) or EPOPC:Chol/DNA (+/−)
(4/1) complexes containing the pCMVtk plasmid (“suicide” gene approach), was
evaluated in TSA cells. Following 4 h incubation with the complexes or HBS (no
transfected cells), the medium was replaced with DMEM-HG containing or not
(control cells and transfected cells non-treated with GCV) different concentra-
tions of GCV (1, 25, 50 or 100 μM). Cells were further incubated for 6 days in
cultured conditions (in 5% CO2 at 37 °C). The medium with or without GCV
was replaced daily and the cell viability was accessed every other day by a
modified Alamar Blue assay [23]. Briefly, 1 ml of 10% (v/v) Alamar Blue dye in
complete DMEM-HG medium was added to each well. After 3 h of incubation at
37 °C, 200 μl of the supernatant were collected from each well and transferred
to 96-well plates. The absorbance at 570 nm and 600 nm was measured in a
Mediators PhL luminometer (Mediators Diagnostika, Vienna, Austria). Cell
viability (as a percentage of control cells) was calculated according to the
formula (A570− A600) of treated cells×100/ (A570−A600) of control cells.
2.5. Ex vivo antitumoral activity
TSA cells were transfected in vitro using the HSA-EPOPC:Chol/DNA (+/−)
(4/1) complexes containing the different plasmids (pCMVluc; pCMVIL-12;
pCMVtk) or simply incubated with HBS. After 4 h incubation (in 5% CO2 at
37 °C) with the different complexes or HBS, the medium was replaced with
DMEM-HG containing 10% FBS and the cells were further incubated for 24 h.
After being detached with trypsin and washed two times with PBS, the cells were
resuspended in PBS saline buffer, to obtain a cell density of 500×103 cells/ml.
200 μl of this cell suspension (100×103 cells) were immediately injected sub-
cutaneously in the left flank of female 8-week-old BALB/c mice (six animals per
group). The animals injected with cells previously transfected with the HSV-tk
gene (pCMVtk plasmid) were submitted to seven intraperitonial administrations
of GCV (75 mg/kg), performed from the day of cell injection during 7 con-
secutive days. Tumor growth was monitored every 5 days by measuring two
perpendicular tumor diameters with a calliper. Mice were sacrificed when the
tumor volume reached approximately 1 cm3.
2.6. In vivo antitumoral activity: tumor implantation and treatment
After being detached with trypsin and washed two times with PBS, TSA cells
were resuspended in PBS saline buffer, to obtain a final cell density of 500×103
cells/ml. 200 μl of this cell suspension (100×103 cells) were immediately injected
subcutaneously in the left flank of female 8-week-old BALB/c mice. When the
Fig. 1. Effect of complex composition and charge ratio (+/−) on luciferase gene
expression in TSA cells. Cells were covered with 0.3 ml of DMEM-HG prior to
the addition of cationic liposome/DNA complexes. EPOPC:Chol liposomes pre-
incubated or not with HSA (32 μg/μg of DNA), were complexed with 1 μg of
pCMVluc at the indicated lipid/DNA charge ratios. After 4 h incubation, the
medium was replaced with DMEM-HG and the cells were further incubated for
48 h. The level of luciferase gene expression was evaluated as described in
Materials and methods. The data are expressed as RLU of luciferase per mg of
total cell protein (mean±standard deviation obtained from triplicates), and are
representative of at least three independent experiments.
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the animals were submitted to different treatments (six animals per group). These
consisted of four intratumoral administrations of 50 μl of the variousHSA-EPOPC:
Chol/DNA (+/−) (4/1) complexes (prepared with different plasmids and using 10,
20 or 40 μg of DNA/administration) at days 0, 3, 5 and 7. The animals that were
treated with the complexes containing the pCMVtk plasmid were submitted to five
(100 mg/kg) or seven (75 mg/kg) intraperitonial administrations of GCV,
performed from the third day after the first treatment during 5 or 7 consecutive
days, respectively. Tumor growth was monitored every 5 days by measuring two
perpendicular tumor diameters with a calliper.Micewere sacrificedwhen the tumor
volume reached approximately 1 cm3.
2.7. In vivo antitumoral activity: tumoral infiltration of T cells and
histological analysis
The subcutaneous tumors induced with TSA cells in female 8-week-old
BALB/c mice were treated as mentioned in the previous section. Twelve days after
the beginning of treatment, animals were sacrificed and tumors were extracted,
embedded in OCT compound (Miles Laboratories, Inc., Elkhart, IN), snap-frozen
in liquid nitrogen and stored at − 80 °C. For immunohistochemistry, 6 μm cryostat
sections were fixed in acetone, blocked using 10% FBS and incubated for 1 h with
a FITC-labeled rat antimouse mAb against CD3 protein (Pharmingen, BD
Biosciences, San José, USA). Unbound antibody was removed by washing with
PBS and tumor sections were counterstainedwith hematoxylin. Sections were then
observed by fluorescence microscopy using a Zeizz Axiovert 200 microscope
(Zeizz, Göttingen, Germany) and the number of immunostained cells was counted
under a microscopic field at 400×magnification. For histological analysis, 6 μm
cryostat tumor sections were fixed in acetone and stained with hematoxylin and
eosin (H&E) and then observed under a Nikon Eclipse E600 microscope (Nikon,
Japan).3. Results
3.1. In vitro biological activity of the cationic liposome/DNA
complexes
The results presented in Fig. 1 show the influence of complex
composition and charge ratio (+/−) on their biological activity in
TSA cells, as assessed by luciferase gene expression. As evident
from this figure, the biological activity mediated by the
complexes EPOPC:Chol/DNA prepared at 2/1 (+/−) charge
ratio is higher than that observed when these are prepared at 1/1
and 4/1 (+/−) charge ratios. Moreover, it is possible to verify that
association of albumin to the EPOPC:Chol/DNA complexes
strongly potentiates their biological activity for any charge ratio.
However, the highest biological activity increase, induced by
albumin association, was observed for complexes prepared at 4/1
(+/−) charge ratio, this being the most efficient HSA-lipoplex
formulation (Fig. 1). Since HSA-EPOPC:Chol/DNA (+/−) (4/1)
complexes are those mediating the highest levels of transfection
and, as demonstrated in our previous work [9], exhibiting
favourable properties for gene delivery (high degree of DNA
protection, surface charge close to neutrality and reduced
interaction with serum components), this formulation was
selected for further studies involving the delivery of therapeutic
genes both in vitro and in vivo cancer models.
3.2. In vitro antitumoral activity of the HSV-tk/GCV strategy
Before testing the antitumoral effect of HSV-tk/GCV
approach in an animal model, we studied the in vitro sensitivityof TSA cells to this strategy, in order to predict its in vivo
therapeutic potential.
Fig. 2 shows the cytotoxic effect of ganciclovir in TSA cells
previously transfected with EPOPC:Chol/DNA (+/−) (4/1) or
HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes, containing
the HSV-tk gene. The results are expressed as the percentage
of cell viability with respect to control cells, cells that were not
treated with GCV. The results presented show that GCV
treatment promotes a significant death of TSA transfected
cells, which increases with both incubation time and GCV
concentration. However, the extent of cytotoxicity observed for
TSA cells transfected with EPOPC:Chol/DNA (+/−) (4/1)
complexes, followed by 6 days of GCV treatment (100 μM),
was much lower than that observed for TSA cells transfected
with HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes under the
same experimental conditions. Two days after transfection with
HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes followed by
GCV treatment, only a slight decrease in the cell viability was
observed. However, 6 days after transfection following GCV
treatment a significant extent of cytotoxicity is achieved for
concentrations of GCV higher than 25 μM, approximately
95% of cell death being observed upon cell treatment with
100 μM GCV. This high cytotoxicity is not due to the drug
itself or transfection protocol, since 6 days after incubation of
non-transfected TSA cells with 100 μM GCVor transfection in
the absence of GCV no significant cell death was observed
(Fig. 2).
3.3. Ex vivo antitumoral activity of the gene therapy strategies
In order to evaluate the potential of the different therapeutic
strategies for ex vivo application, cells were transfected with the
Fig. 2. Effect of ganciclovir concentration on the viability of TSA cells. Cells
were covered with 0.3 ml of DMEM-HG before the addition of 200 μl of HSA-
EPOPC:Chol/DNA (+/−) (4/1) complexes (transfected cells-T(HSA): solid line)
or 200 μl of EPOPC:Chol/DNA (+/−) (4/1) complexes (transfected cells-T:
broken line), containing the pCMVtk plasmid, or 200 μl of HBS (non-
transfected cells: dot line). After 4 h incubation, the medium was replaced with
DMEM-HG (control cells and transfected cells non-treated with GCV) or with
DMEM-HG containing different concentrations of ganciclovir (1, 25, 50 or
100 μM) and the cells were further incubated for 6 days. The medium with or
without GCV was replaced daily and cell viability was assessed by the Alamar
Blue assay, as described inMaterials and methods. Cell viability (as a percentage
of control cells) was calculated according to the formula (A570−A600) of treated
cells×100/ (A570−A600) of control cells.
Fig. 3. Effect of the in vitro pre-treatment of TSA cells on the subcutaneous
tumor growth in BALB/c mice. TSA cells were transfected in vitro with the
HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes, containing the different
plasmids (pCMVIL-12, pCMVtk or pCMVluc), or incubated with HBS. After
4 h incubation, the medium was replaced with DMEM-HG containing 10% FBS
and the cells were further incubated for 24 h. Cells were then resuspended in
PBS saline buffer, in order to obtain a final cell density of 500×103 cells/ml, and
200 μl of the cell suspension were immediately injected subcutaneously in the
left flank of female 8-week-old BALB/c mice. Animals injected with cells
transfected with the complexes containing the pCMVtk plasmid were submitted
to seven intraperitonial administrations of GCV (75 mg/kg), performed from the
day of cell injection during 7 consecutive days. Tumor growth was monitored
every 5 days by measuring two perpendicular tumor diameters with a calliper.
The data are expressed as mean tumor volume (cm3) and represent the mean±
standard deviation obtained from six animals. Mice were sacrificed when the
tumor volume reached approximately 1 cm3.
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inoculated to induce the tumor. The percentage of transfected
cells was approximately 15%.
Fig. 3 shows the results of tumor growth after a
subcutaneous injection, in the left flank of female 8-week-
old BALB/c mice, of 100×103 TSA cells previously submitted
to different transfection conditions. As can be observed,
inoculation of HBS-treated cells induces tumors that exhibit a
higher size and growth kinetics than cells previously
transfected with HSA-EPOPC:Chol/DNA (+/−) (4/1) com-
plexes, containing the luciferase gene (control complexes). On
the other hand, tumors resulting from subcutaneous injection
of cells previously transfected with HSA-EPOPC:Chol/DNA
(+/−) (4/1) complexes containing the IL-12 gene or the HSV-tk
gene (in this case mice were submitted to seven intraperitonial
administrations of GCV (75 mg/kg), performed from the day
of cell injection during 7 consecutive days) are not only much
smaller, but begin to develop later, as compared to those
induced upon inoculation of cells transfected with the control
complexes. Moreover, under both conditions, 33 days after
inoculation of the cells, the tumor volume is approximately
three times smaller than that of animals injected with cells
previously transfected with the control complexes (Fig. 3). It
should be emphasized that differences between tumor sizes
cannot be due to differences in the viability of injected cells,
since for all experimental conditions each animal was injected
with 100×103 viable TSA cells.3.4. In vivo antitumoral activity of the gene therapy strategies
Three distinct therapeutic strategies were evaluated in vivo
using the HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes: the
“suicide” gene therapy, previously tested in vitro, involving
intratumoral administration of complexes containing the HSV-
tk gene followed by GCV treatment; the immuno-gene-therapy,
involving intratumoral administration of complexes containing
the IL-12 gene; the combination of both strategies, involving the
intratumoral administration of complexes containing both the
IL-12 and the HSV-tk genes, and subsequent treatment with
GCV. These strategies were tested in female BALB/c mice
bearing a subcutaneous tumor with a volume of approximately
0.02 cm3, resulting from the inoculation of 100×103 TSA cells
in the left flank 9 days before the first gene treatment. These
subcutaneous tumors are characterized for being aggressive,
poorly immunogenic and exhibiting high proliferation capacity
[14,24].
Fig. 4 shows the results obtained for the inhibition of tumor
growth after application of the different gene therapy strategies.
These consisted of four intratumoral administrations of 50 μl of
HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes or HBS (Fig.
4B), performed on days 0, 3, 5 and 7 after tumor implantation.
The animals treated with complexes containing the HSV-tk
gene were submitted to seven intraperitonial administrations of
GCV (75 mg/kg), performed from day 3 during 7 consecutive
days. As shown in Fig. 4A, four intratumoral administrations of
the complexes containing 40 μg of plasmid encoding either IL-
12 or HSV-tk or four intratumoral administrations of complexes
Fig. 4. Antitumoral effect of different gene therapy strategies against
subcutaneous tumors induced with TSA cells in BALB/c mice. Animals were
treated with HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes containing: (A)
40 μg of plasmid DNA or (B) different amounts of plasmid DNA (10, 20 or
40 μg). 200 μl of TSA cells (100×103 cells) were injected subcutaneously into
the left flank of female 8-week-old BALB/c mice. When tumor volume reached
approximately 0.02 cm3, usually 9 days after cell injection, the animals were
submitted to different treatments, which consisted of four intratumoral
administrations of 50 μl of HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes or
50 μl of HBS (non-treated) performed on days 0, 3, 5 and 7. The therapeutic
complexes contained different amounts of the pCMVIL-12 plasmid (IL-12) or
pCMVtk plasmid (HSV-tk), while control complexes contained pCMVluc
plasmid. Animals treated with the complexes containing the pCMVtk plasmid
were submitted to seven intraperitonial administrations of GCV (75 mg/kg),
performed from day 3 after the first gene treatment during 7 consecutive days.
Tumor growth was monitored every 5 days by measuring two perpendicular
tumor diameters with a calliper. The data are expressed as mean tumor volume
(cm3) and represent the mean±standard deviation obtained from six animals.
Mice were sacrificed when the tumor volume reached approximately 1 cm3.
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antitumoral effect (P<0.01) when compared to that resulting
from four administrations of control complexes (complexes
containing 40 μg of plasmid encoding luciferase). The
antitumoral activity of the combined gene therapy strategy
was similar to that observed when only immuno-gene therapy or
“suicide” gene therapy were tested (Fig. 4A). It should be noted
that, in the group of six animals submitted to the immuno-gene
therapy treatment, a complete tumor regression was observed in
one of the mice.
Fig. 4B shows the importance of the therapeutic gene dose on
the observed antitumoral effect. As illustrated, four intratumoraladministrations of complexes containing 10 μg of plasmid
encoding IL-12 have the same effect as that for control
complexes, while four intratumoral administrations of com-
plexes prepared with 40 μg of plasmid containing the IL-12 gene
resulted in a significant reduction in tumor growth (P<0.01),
when compared to that of control complexes. However, four
intratumoral administrations of control complexes promoted, by
itself, a slight antitumoral effect (P<0.05) when compared to
that observed in HBS-treated animals (Fig. 4B).
It should be noted that parallel studies involving two
intratumoral administrations of the complexes, resulted in a
smaller antitumoral effect than that achieved upon four
intratumoral administrations (data not show).
3.5. In vivo antitumoral activity: evaluation of T-lymphocyte
tumor infiltration
The antitumoral activity of the immuno-gene therapy and
“suicide” gene therapy strategies involves the activation of the
immune system against the neoplastic tissue, although most
likely through different pathways. Since T-lymphocytes
greatly contribute to the antitumoral responses induced by
the immune system, we evaluated the tumoral infiltration of T-
lymphocytes following application of the above mentioned
strategies.
Fig. 5 illustrates the tumoral infiltration of T-lymphocytes,
as assessed by immunohistochemistry using a rat antimouse
FITC-labeled mAb against CD3 protein, 12 days after the first
gene therapy treatment of TSA subcutaneous tumors. Tumors
from animals submitted to four intratumoral administrations of
control complexes (HSA-EPOPC:Chol/DNA (+/−) (4/1) com-
plexes prepared with 40 μg of plasmid containing the
luciferase gene) presented a more extensive T-lymphocyte
infiltration than those from non-treated animals. However, for
animals treated with four intratumoral administrations of HSA-
EPOPC:Chol/DNA (+/−) (4/1) complexes, containing 40 μg of
plasmid encoding IL-12, extensive T-lymphocyte infiltration
was elicited, this being much more significant than that
registered in tumors from animals treated with control
complexes. It is interesting to observe that in the case of
animals submitted to four intratumoral administrations of the
complexes, containing 40 μg of plasmid encoding HSV-tk, T-
lymphocyte infiltration was higher than that in tumors from
animals treated with control complexes, but less extensive than
in tumors from animals submitted to the immuno-gene therapy
protocol (Fig. 5).
3.6. In vivo antitumoral activity: analysis of tumor histology
The studies of tumoral infiltration of T-lymphocytes were
complemented by tumor histological analysis, performed 12
days after the first gene therapy treatment of TSA subcutaneous
tumors, using the hematoxylin and eosin assay. The results
shown in Fig. 6 demonstrate the absence of any significant
necrotic and hemorrhagic areas or leukocyte infiltration in
tumors from non-treated animals. In the case of tumors from
animals submitted to four intratumoral administrations of control
Fig. 5. Effect of different gene therapy strategies on tumor T lymphocyte infiltration. (A) Representative images of T-lymphocyte tumor infiltration obtained by
fluorescence microscopy (original magnification: ×400); (B) number of immunostained cells counted under a ×400 microscopic field (mean±standard deviation
obtained from 10 fields). (a) and (NT) tumor from non-treated animal; (b) and (Control) tumor from animal treated with complexes containing pCMVluc plasmid;
(c) and (IL-12) tumor from animal treated with complexes containing pCMVIL-12 plasmid; (d) and (HSV-tk) tumor from animal treated with complexes prepared with
pCMVtk plasmid. Induction of tumor and treatment was performed as described in the legend to Fig. 4. Twelve days after the first of gene therapy treatment, animals
were sacrificed, tumors were removed and 6 μm cryostat sections were incubated with a rat antimouse FITC-labeled mAb against CD3 protein.
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containing 40 μg of plasmid encoding luciferase), a few necrotic
and hemorrhagic areas as well as low leukocyte infiltration were
observed. On the other hand, tumors from animals treated with
four intratumoral administrations of complexes containing 40 μg
of plasmid encoding either IL-12 or HSV-tk presented extensive
areas of necrosis and hemorrhage with leukocyte infiltration in
all cases. Although a significant leukocyte infiltration was
observed under both therapeutic conditions, this was more
evident for the immuno-gene therapy treatment than for the
“suicide” gene therapy strategy, not only near these areas of
destruction but also in the other areas of the tumor.4. Discussion
The results obtained in this work show that association of
albumin to EPOPC:Chol/DNA lipoplexes, through the estab-
lishment of electrostatic interactions between the negative
charges of the protein and the positive charge of cationic
liposomes, significantly increases transfection activity in TSA
cells (Fig. 1). These observations are in agreement with our
previous published results which have shown that lipoplexes
containing the new cationic lipid EPOPC exhibit a higher
transfection activity (more than 2-fold) than the conventional
DOTAP:Chol/DNA lipoplexes and that association of albumin
Fig. 6. Effect of different gene therapy strategies on the tumor histology. Representative images: (a) tumor from non-treated animal; (b) tumor from animal treated with
complexes prepared with pCMVluc plasmid; (c) tumor from animal treated with complexes containing pCMVIL-12 plasmid; (d) tumor from animal treated with
complexes prepared with pCMVtk plasmid. Induction of tumor and treatment was performed as described in the legend to Fig. 4. Twelve days after the first gene
therapy treatment, animals were sacrificed, tumors were removed and 6 μm cryostat sections were stained with hematoxylin and eosin (H&E).
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Similarly to what was observed for COS-7 cells, an enhancing
effect on transfection of TSA cells was observed upon
association of albumin to EPOPC:Chol/DNA lipoplexes, this
effect being particularly pronounced at the 4/1 lipid/DNA (+/−)
charge ratio (Fig. 1).
Although the exact mechanism of the enhancing effect
induced by albumin on the biological activity of the lipoplexes
is not known, previous experiments showed that the HSA-
lipoplexes could bind non-specifically to cell surface receptors,
analogous to scavenger receptors, which in turn mediate their
endocytosis, resulting in a transfection enhancement [25,26].
Moreover, albumin can facilitate the escape of DNA from the
endocytotic pathway, since this protein has been described as
being able to undergo a low pH-induced conformational
change, thereby acquiring fusogenic properties [27,28]. Thus,
the partial protonation of HSA at endosomal pH and itssubsequent interaction with the endosome membrane may be
involved in the destabilization of the latter and, consequently, in
the cytoplasmic delivery of DNA.
Our previous results also showed that, like in vitro, the
HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes are signifi-
cantly more efficient in mediating in vivo transfection than
EPOPC:Chol/DNA (+/−) (4/1) complexes, since upon intra-
venous administration the biological activity observed with the
former was much higher (more than 5-fold) than with the latter
[9]. However, the highest levels of transfection for both
formulations (complexes with and without albumin) have been
observed in the lung. This could be most likely attributed to
the large size of the complexes that promotes their rapid
elimination from the blood circulation, mainly due to their
retention in the lung. This fact limits the intravenous
administration of lipoplexes for therapeutic applications that
do not involve the lung or blood tissues. However, their in situ
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ches, such as those involving solid tumors.
As observed from our in vitro and in vivo studies using a
reporter gene, the experiments performed in vitro, using the
HSV-tk/GCV “suicide” gene therapy strategy, show that
HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes are signifi-
cantly more efficient in mediating transfection than EPOPC:
Chol/DNA (+/−) (4/1) complexes. In fact, the extent of cell
death observed for TSA cells transfected with the albumin-
associated complexes was much higher than that observed for
complexes without albumin (Fig. 2). The application of this
gene therapy strategy mediated by HSA-EPOPC:Chol/DNA
(+/−) (4/1) lipoplex formulation, resulted in approximately
100% TSA cell death, showing the therapeutic potential of
this strategy. This strong cytotoxicity shows the occurrence of
the bystander effect, since the percentage of transfected cells
(approximately 15%) was much lower than the percentage of
cell death. The bystander effect is due to transfer of toxic
GCV metabolites from HSV-tk transfected cells, through gap
junctions and/or by phagocytosis of “apoptotic” vesicles
(containing toxic GCV metabolites), to non-transfected cells
[17,19,29–31].
Therefore, based on the above mentioned findings, we tested
the efficacy of this new albumin-associated lipoplex formula-
tion (HSA-EPOPC:Chol/DNA (+/−) 4/1 complexes) in anti-
tumoral gene therapy strategies.
The antitumoral activity studies performed in the animal
model (female BALB/c mice bearing a flank TSA tumor)
show that application of any of the three tested therapeutic
strategies, “suicide” gene therapy, immuno-gene therapy and
the combination of both strategies, resulted in a significant
antitumoral effect. In fact, four intratumoral administrations
of the HSA-EPOPC:Chol/DNA (+/−) 4/1 complexes contain-
ing 40 μg of plasmid encoding either IL-12 or HSV-tk, or
20 μg of each plasmid, resulted in a significant reduction in
tumor growth when compared to the effect of four
intratumoral administrations of control complexes (the same
formulation containing 40 μg of plasmid encoding luciferase)
(Fig. 4A). However, control complexes induced, by itself, a
slight antitumoral effect, since tumors from animals treated
with these complexes were slightly smaller than those from
non-treated (data not shown) or treated animals with HBS
(Fig. 4B).
Several studies have demonstrated that lipoplex adminis-
tration into the lung lumen promotes the production of pro-
inflammatory cytokines including TNF-α, IFN-γ and IL-12,
which are accompanied by a pulmonary influx of polymorpho-
nuclear cells [32,33]. Moreover, it has been shown that
intravenous administration of lipoplexes into mice promotes a
similar effect, inducing an immune response that limits
subsequent administrations of lipoplexes within a short time
period [34]. On the other hand, it has been shown that this
effect is not elicited by the lipid component of the cationic
liposome/DNA complexes, by itself, and cannot also be
attributed to the presence of endotoxins in the plasmid
preparation [32–35]. It has been reported that the cytosine–
phosphate–guanine (CpG) motifs, present in the DNA plasmidvectors, are responsible for most of the immunostimulatory
effects of cationic liposome/DNA complexes, since the
methylation or elimination of these motifs resulted in a strong
reduction in cytokine production [36–38]. In this context, it is
important to emphasize that reduction of tumor growth has been
observed following administration of lipoplexes prepared with
plasmids lacking therapeutic genes but containing CpG motifs,
which is not achieved upon methylation of these sequences
[39–41].
Taking into account these findings, the slight antitumoral
effect observed after four intratumoral administrations of
control HSA-EPOPC:Chol/DNA (+/−) 4/1 complexes was
probably due to immunostimulation provoked by CpG motifs,
present in the plasmid DNA of the complexes [41]. However,
in agreement with other authors, this immunomodulatory effect
was enhanced by the complexes, particularly, by the presence
of human albumin [42]. Thus, HSA association to lipoplexes
may contribute to the antitumoral effect of the tested
therapeutic strategies not only by strongly increasing the
expression of the therapeutic gene but also leading to an
enhancement of the immune response against the tumor [9,42].
The results on the evaluation of T-lymphocyte tumoral
infiltration, showing that tumors from animals treated with
control complexes present a higher T-lymphocyte infiltration
than those from non-treated animals, reflect the immunosti-
mulatory effect of these complexes (Fig. 5). Moreover, results
from the histological studies (Fig. 6), showing the presence of
some necrotic and hemorrhagic areas and some leukocyte
infiltration in mice treated with control complexes, further
confirm the involvement of an immune response, in agreement
with results reported by other authors [39–41].
On the other hand, the intratumoral administration of the
HSA-EPOPC:Chol/DNA (+/−) 4/1 complexes containing the
IL-12 gene (prepared with 40 μg of plasmid) resulted in a strong
antitumoral effect, as shown by the significant tumor regression
(Fig. 4), high T-lymphocyte infiltration (Fig. 5) and the
extensive necrotic and hemorrhagic areas (Fig. 6). Although
this antitumoral effect was essentially due to the IL-12
expression, a small contribution to this antineoplastic action
resulted from the composition of complexes, as discussed above
[39–42]. The IL-12 antitumoral effect is due to its capacity to
promote proliferation and cytotoxic activity of T-lymphocytes
and NK cells, which induce tumor cell killing and damaging of
tumor vessels. Moreover, these IL-12 activated cells produce
high amounts of INF-γ and others cytokines, such as TNF-α,
which strongly further contribute to tumoral cell death and
vascular destruction, as well as to angiogenesis inhibition
[14,15,43–47]. Among the released cytokines, INF-γ is the
main effector of IL-12 antitumor activities, by promoting
processes like direct destruction of tumoral cells and angiogen-
esis inhibition [14,15]; induction of classes I and II MHC
glycoprotein expression in tumor cells, thereby increasing their
recognition by the immune system [14,17]; production of
chemokines, such as IP-10, MIG and other factors by tumoral
and endothelial cells and by cells from the immune system,
which inhibit tumor angiogenesis and cause vascular damage
[46,47].
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resulted in a significant antitumoral activity that was similar
to that observed for the immuno-gene therapy strategy,
although these two approaches involve different antineoplastic
mechanisms. As previously referred, the “suicide” gene
therapy strategy benefits from the bystander effect, which is
due to the transfer of toxic GCV metabolites from HSV-tk-
transfected to non-transfected tumor cells [17,19,29–31].
However, in vivo, this cell death enhancing effect is also
due to HSV-tk transfection and necrosis of tumor endothelial
cells which cause vessel rupture and ischemia, thereby
inducing a hemorrhagic tumor necrosis. Moreover, in vivo
bystander effect also include local inflammatory responses of
the cellular immune system probably induced by the release
of soluble factors, like TNF-α and IL-1, from HSV-tk-
transfected tumor cells and/or the release of cellular debris
resulting from the necrosis process [19–21]. It is possible that
these mechanisms have been responsible for the significant
antineoplastic effect observed after four intratumoral admin-
istrations of HSA-EPOPC:Chol/DNA (+/−) (4/1) complexes,
containing 40 μg of plasmid encoding HSV-tk, and
subsequent GCV administration (Fig. 4A). Our results from
the evaluation of T-lymphocyte tumoral infiltration (Fig. 5)
and histological studies (Fig. 6) demonstrated the existence of
a strong antitumoral action, involving T-lymphocyte infiltra-
tion and the presence of necrotic and hemorrhagic areas at a
much higher extent than that observed in tumors from animals
treated with control complexes. These findings, which are in
agreement with those reported by others authors, indicate that
the observed host immune responses were involved in the
bystander effect of the HSV-tk/GCV “suicide” gene therapy
strategy [19–21].
The combination of both immuno-gene therapy and
“suicide” gene therapy strategies, through four intratumoral
administrations of the HSA-EPOPC:Chol/DNA (+/−) 4/1
complexes containing 20 μg of plasmid encoding IL-12 and
20 μg of plasmid containing the HSV-tk gene, followed by
GCV administration, also resulted in a significant antitumor
activity when compared to the effect of four intratumoral
administrations of control complexes (Fig. 4A). In spite of
containing only 20 μg of plasmid encoding IL-12 the observed
antitumoral effect mediated by the HSA-associated complexes
was similar to that achieved for the best immuno-gene therapy
condition (40 μg of plasmid encoding IL-12). This was
probably due to the antitumoral action induced by the HSV-
tk/GCV strategy, involving the mechanisms referred to above,
which compensated the lower immunostimulation elicited by
the smaller amount of IL-12 produced in the tumor.
Overall, the present study demonstrates that HSA-EPOPC:
Chol/DNA (+/−) 4/1 complexes constitute a promising system
for the successful application of any of the tested antitumoral
strategies, particularly considering that TSA tumors are
characterized for being poorly immunogenic, aggressive and
exhibiting high proliferation capacity. However, studies on the
optimization of these strategies need to be addressed, namely in
terms of extent and duration of transgene expression, aiming at
achieving a complete tumor regression.Acknowledgements
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